The Medical Advisor

Introduction Obesity is a global health crisis intricately linked to an increased risk of chronic diseases, including various cancers such as pancreatic, lung, and triple-negative breast cancer (TNBC). While medical therapeutics like semaglutide have made strides in managing obesity, newer agents like retatrutide (RETA, LY3437943) are redefining the landscape of weight loss and revealing unexpected benefits in cancer prevention and treatment. Emerging preclinical research highlights retatrutide’s potential not only to induce significant weight loss but also to reduce cancer risk and improve tumor outcomes, offering a dual-purpose therapeutic approach for obese patients. This article explores the groundbreaking findings on retatrutide’s anti-tumor effects and its implications for obesity-associated cancers. Retatrutide’s Impact on Obesity-Associated Cancers Recent studies in preclinical models demonstrate that retatrutide-induced weight loss goes beyond metabolic benefits, exerting pro...